CURRENT
ISSUE1612
November 30, 2020
The investigational neutralizing IgG1 monoclonal
antibody bamlanivimab (LY-CoV555; Lilly) has
been granted an FDA Emergency Use Authorization
(EUA) for treatment of recently diagnosed mild
to moderate COVID-19 in patients who are ≥12
years old, weigh at least 40 kg, and are at high
risk for progressing to severe disease and/or
hospitalization (see Table... read more...
More from issue 1612
Coming Soon
Drugs for Asthma
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
Ofatumumab (Kesimpta) for Multiple Sclerosis
An EUA for Baricitinib for COVID-19
An EUA for Casirivimab and Imdevimab - A Monoclonal Antibody Combination for COVID-19
Recommend to Your Library
Previous Issues
November 16, 2020 (1611)
- In Brief: Hydrochlorothiazide and Skin Cancer
- Empagliflozin (Jardiance) for Heart Failure
- Minocycline Foam (Zilxi) for Rosacea
- Orphengesic Forte - An Old Analgesic Combination Returns
- Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
- Comparison Chart: SGLT2 Inhibitors (online only)
November 2, 2020 (1610)
- Antiviral Drugs for Influenza for 2020-2021
- Large-Volume, Preservative-Free Albuterol Concentrate
- In Brief: New Benzodiazepine Warnings
- In Brief: New Warnings on NSAID Use in Pregnancy
- In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
- Expanded Table: Antiviral Drugs for Influenza (online only)
October 19, 2020 (1609)
- Timing of Remdesivir for COVID-19
- Lyumjev - A New Insulin Lispro for Diabetes
- Caplacizumab (Cablivi) for iTTP
- Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
- Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
- Two New Doses of Dulaglutide (Trulicity) for Diabetes
October 5, 2020 (1608)
September 21, 2020 (1607)
